Scleroderma Skin

Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial

Diffuse cutaneous systemic sclerosis (dcSSc) is one…

Comparison of immunosuppressants for early diffuse systemic sclerosis yields mixed results

Placing patients who have early diffuse cutaneous systemic sclerosis (dcSSc ) on an immunosuppressant regimen can have a beneficial, but not necessarily sustainable, impact, according to findings from the European Scleroderma Observational Study.

Lymphotoxin B and Adipose Derived Stromal Cells Regulate Skin Fibrosis in Scleroderma

Researchers at the Hospital for Special Surgery in New York City have identified a possible mechanism underlying the fibrosis of scleroderma (SSc) skin disease.

Pharmacological inhibition of porcupine induces regression of experimental skin fibrosis by targeting Wnt signalling

Objectives Wnt signalling has been implicated in activating a fibrogenic programme in fibroblasts in systemic sclerosis (SSc). Porcupine is an O-acyltransferase required for secretion of Wnt proteins in mammals. Here, we aimed to evaluate the antifibrotic effects of pharmacological inhibition of por…

Potential Scleroderma Therapy Seen to Stop Inflammation in Phase 1 Trial

Read about a potential scleroderma treatment, Resunab by Corbus, that in a Phase 1 study showed efficacy in ending inflammation and was seen to be safe.

Targeted Therapy for Scleroderma Fibrosis

Scleroderma, or systemic sclerosis (SSc), is an autoimmune disease characterized by vasculopathy and fibrosis. Although relatively rare, with a…